BACKGROUND: Clinical studies demonstrate increased prevalence of human papillomavirus (HPV)-associated disease in HIV-infected individuals and an increased risk of HIV acquisition in HPV-infected individuals. The mechanisms underlying this synergy are not defined. We hypothesize that women with cervical intraepithelial neoplasia (CIN) will exhibit changes in soluble mucosal immunity that may promote HPV persistence and facilitate HIV infection. METHODS: The concentrations of immune mediators and endogenous anti-Escherichia coli activity in genital tract secretions collected by cervicovaginal lavage were compared in HIV-negative women with high-risk HPV-positive (HRHPV+) CIN-3 (n = 37), HRHPV+ CIN-1 (n = 12), or PAP-negative control subjects (n = 57). RESULTS: Compared with control subjects, women with CIN-3 or CIN-1 displayed significantly higher levels of proinflammatory cytokines including interleukin (IL)-1α, IL-1β, and IL-8 (P < 0.002) and significantly lower levels of anti-inflammatory mediators and antimicrobial peptides, including IL-1 receptor antagonist, secretory leukocyte protease inhibitor (P < 0.01), and human β defensins 2 and 3 (P < 0.02). There was no significant difference in endogenous anti-E. coli activity after controlling for age and sample storage time. CONCLUSION: HRHPV+ CIN is characterized by changes in soluble mucosal immunity that could contribute to HPV persistence. The observed mucosal inflammation suggests a mechanism that may also contribute to the epidemiologic link between persistent HPV and HIV.
BACKGROUND: Clinical studies demonstrate increased prevalence of human papillomavirus (HPV)-associated disease in HIV-infected individuals and an increased risk of HIV acquisition in HPV-infected individuals. The mechanisms underlying this synergy are not defined. We hypothesize that women with cervical intraepithelial neoplasia (CIN) will exhibit changes in soluble mucosal immunity that may promote HPV persistence and facilitate HIV infection. METHODS: The concentrations of immune mediators and endogenous anti-Escherichia coli activity in genital tract secretions collected by cervicovaginal lavage were compared in HIV-negative women with high-risk HPV-positive (HRHPV+) CIN-3 (n = 37), HRHPV+ CIN-1 (n = 12), or PAP-negative control subjects (n = 57). RESULTS: Compared with control subjects, women with CIN-3 or CIN-1 displayed significantly higher levels of proinflammatory cytokines including interleukin (IL)-1α, IL-1β, and IL-8 (P < 0.002) and significantly lower levels of anti-inflammatory mediators and antimicrobial peptides, including IL-1 receptor antagonist, secretory leukocyte protease inhibitor (P < 0.01), and human β defensins 2 and 3 (P < 0.02). There was no significant difference in endogenous anti-E. coli activity after controlling for age and sample storage time. CONCLUSION:HRHPV+ CIN is characterized by changes in soluble mucosal immunity that could contribute to HPV persistence. The observed mucosal inflammation suggests a mechanism that may also contribute to the epidemiologic link between persistent HPV and HIV.
Authors: Caroline Mitchell; Jane Hitti; Kathleen Paul; Kathy Agnew; Susan E Cohn; Amneris E Luque; Robert Coombs Journal: AIDS Res Hum Retroviruses Date: 2010-10-07 Impact factor: 2.205
Authors: Victor H Ferreira; Aisha Nazli; Ghaznia Khan; M Firoz Mian; Ali A Ashkar; Scott Gray-Owen; Rupert Kaul; Charu Kaushic Journal: J Infect Dis Date: 2011-07-15 Impact factor: 5.226
Authors: Anil K Chaturvedi; Hormuzd A Katki; Allan Hildesheim; Ana Cecilia Rodríguez; Wim Quint; Mark Schiffman; Leen-Jan Van Doorn; Carolina Porras; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Rolando Herrero Journal: J Infect Dis Date: 2011-04-01 Impact factor: 5.226
Authors: Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold Journal: J Virol Date: 2008-07-30 Impact factor: 5.103
Authors: Qingsheng Li; Jacob D Estes; Patrick M Schlievert; Lijie Duan; Amanda J Brosnahan; Peter J Southern; Cavan S Reilly; Marnie L Peterson; Nancy Schultz-Darken; Kevin G Brunner; Karla R Nephew; Stefan Pambuccian; Jeffrey D Lifson; John V Carlis; Ashley T Haase Journal: Nature Date: 2009-03-04 Impact factor: 49.962
Authors: Karen K Smith-McCune; Stephen Shiboski; Mike Z Chirenje; Tsitsi Magure; Jennifer Tuveson; Yifei Ma; Maria Da Costa; Anna-Barbara Moscicki; Joel M Palefsky; Rudo Makunike-Mutasa; Tsungai Chipato; Ariane van der Straten; George F Sawaya Journal: PLoS One Date: 2010-04-08 Impact factor: 3.240
Authors: Nicola Low; Matthew F Chersich; Kurt Schmidlin; Matthias Egger; Suzanna C Francis; Janneke H H M van de Wijgert; Richard J Hayes; Jared M Baeten; Joelle Brown; Sinead Delany-Moretlwe; Rupert Kaul; Nuala McGrath; Charles Morrison; Landon Myer; Marleen Temmerman; Ariane van der Straten; Deborah Watson-Jones; Marcel Zwahlen; Adriane Martin Hilber Journal: PLoS Med Date: 2011-02-15 Impact factor: 11.069
Authors: Niall Buckley; Ashley Huber; Yungtai Lo; Philip E Castle; Kimdar Kemal; Robert D Burk; Howard D Strickler; Mark H Einstein; Mary Young; Kathryn Anastos; Betsy C Herold Journal: Am J Reprod Immunol Date: 2015-12-18 Impact factor: 3.886
Authors: Sharon A Greene; Christine J McGrath; Dara A Lehman; Kara G Marson; T Tony Trinh; Nelly Yatich; Evans Nyongesa-Malava; Catherine Kiptinness; Barbra A Richardson; Grace C John-Stewart; Hugo De Vuyst; Samah R Sakr; Nelly R Mugo; Michael H Chung Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Kerry Murphy; Barbra A Richardson; Charlene S Dezzutti; Jeanne Marrazzo; Sharon L Hillier; Craig W Hendrix; Betsy C Herold Journal: Am J Reprod Immunol Date: 2015-06-21 Impact factor: 3.886
Authors: Jeny P Ghartey; Colleen Carpenter; Philip Gialanella; Charlotte Rising; Thomas C McAndrew; Mohak Mhatre; Jessica Tugetman; Mark H Einstein; Cynthia Chazotte; Betsy C Herold Journal: Am J Obstet Gynecol Date: 2012-07-26 Impact factor: 8.661
Authors: Jeny Ghartey; Andrea Kovacs; Robert D Burk; L Stewart Massad; Howard Minkoff; Xianhong Xie; Gypsyamber Dʼsouza; Xiaonan Xue; D Heather Watts; Alexandra M Levine; Mark H Einstein; Christine Colie; Kathryn Anastos; Isam-Eldin Eltoum; Betsy C Herold; Joel M Palefsky; Howard D Strickler Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731